EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center

Franciscus A Diepstraten iD, Odette M M Bertram, Hiske W Helleman, Ralf A Boerboom, Martine van Grotel iD, József Zsíros, Godelieve A M Tytgat, Harm van Tinteren iD, Robert J Stokroos, Geert O Janssens, Alex E Hoetink, Marry M van den Heuvel-Eibrink und 1 weitere

Cancer Reports · 2024

DOI: 10.1002/cnr2.70046 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Cancer Reports, 2024. Verfasst von Franciscus A Diepstraten und 12 weiteren Autor:innen. Beteiligte Einrichtung: Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands. Hauptthemen laut MEDLINE: Ototoxicity, Neoplasms. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 42 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Introduction

Ototoxicity is an adverse effect of childhood cancer treatment with a negative impact on speech‐language development and quality of life. This study aimed to retrospectively assess ototoxicity monitoring in a national cohort of pediatric patients with solid tumors, examining the frequency and determinants associated with hearing loss (HL).

Methods

This retrospective cohort study included 305 patients treated between 2015 and 2020 at the Princess Máxima Center. Patients receiving platinum agents, head and neck radiotherapy, and/or ear‐nose‐throat surgery were analyzed. Electronic patient files provided demographic, clinical, and audiological data. HL was defined as Muenster ≥ 2b or SIOP ≥ 2 grade. Associations between clinical characteristics and HL occurrence were analyzed using logistic regression analysis.

Results

Audiological monitoring was performed at baseline (62.6%), during treatment (79.0%), and at the end of treatment (82.1%). Post treatment, 51.2% and 36.5% experienced Muenster and SIOP‐defined HL, respectively. Multivariable analyses revealed that age at diagnosis (OR 0.9, 95% CI 0.9–1.0), total cumulative dose cisplatin per 100 mg/m 2 (OR 1.6, 95% CI 1.4–2.0), and vincristine treatment (OR 3.3, 95% CI 1.4–7.8) remained significantly associated with Muenster grade ≥ 2b HL. Age at diagnosis in years (OR 0.9, 95% CI 0.8–1.0), total cumulative dose cisplatin per 100 mg/m 2 (OR 1.5, 95% CI 1.2–1.8), and male sex (OR 2.7, 95% CI 1.4–5.3) were associated with SIOP ≥ 2 HL.

Conclusion

This study shows that more than half of the children treated with ototoxic cancer therapies develop HL by the end of treatment. Therefore, audiological monitoring during and after treatment is essential. Improved insight into clinical determinants aids in identifying patients at high risk for HL, who may benefit from prevention strategies that are currently being implemented.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

OtotoxicityNeoplasmsHumansMaleRetrospective StudiesFemaleChildChild, PreschoolAdolescentNetherlandsAntineoplastic AgentsInfantHearing LossCisplatinQuality of LifeRisk Factors

Stichwörter der Autor:innen

audiologychildhood cancerototoxicitysolid tumors

Substanzen

Antineoplastic AgentsCisplatin

Autor:innen und Institutionen

  • Princess Máxima Center for Pediatric Oncology, Utrecht, Netherlands.
  • Department of Audiology, University Medical Center Utrecht, Utrecht, Netherlands.
  • Department of Otorhinolaryngology-Head and Neck Surgery, University Medical Center Utrecht, Utrecht, Netherlands.
  • UMC Brain Center, University Medical Center Utrecht, Utrecht, Netherlands.
  • Department of Radiation Oncology, University Medical Center Utrecht, Utrecht, Netherlands.
  • University Medical Center Utrecht-Wilhelmina Children's Hospital, Utrecht, Netherlands.

ORCID-Profile: Franciscus A Diepstraten, Martine van Grotel, Harm van Tinteren

Zitieren

APA

Diepstraten, F. A., Bertram, O. M. M., Helleman, H. W., Boerboom, R. A., van Grotel, M., Zsíros, J., Tytgat, G. A. M., van Tinteren, H., Stokroos, R. J., Janssens, G. O., Hoetink, A. E., van den Heuvel-Eibrink, M. M., & Meijer, A. J. M. (2024). A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center. Cancer Reports. https://doi.org/10.1002/cnr2.70046

Vancouver

Diepstraten FA, Bertram OMM, Helleman HW, Boerboom RA, van Grotel M, Zsíros J, et al. A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center. Cancer Reports. 2024. doi:10.1002/cnr2.70046

BibTeX
@article{Diepstraten2024,
  author = {Diepstraten, Franciscus A and Bertram, Odette M M and Helleman, Hiske W and Boerboom, Ralf A and van Grotel, Martine and Zsíros, József and Tytgat, Godelieve A M and van Tinteren, Harm and Stokroos, Robert J and Janssens, Geert O and Hoetink, Alex E and van den Heuvel-Eibrink, Marry M and Meijer, Annelot J M},
  title = {A Retrospective Evaluation of Ototoxicity Monitoring in a Cohort of Pediatric Patients With Solid Tumors, Treated in the Dutch National Cancer Center},
  journal = {Cancer Reports},
  year = {2024},
  doi = {10.1002/cnr2.70046}
}
Kostenlos starten →